SLIDE 2 20 Novemb My Fellow In recent w The 36th a designed to current ant choice but
Company m This is the stepping st determinati significanc desired by Much has b Looking ah
portfolio of Importantly now suppo beneficial a A disciplin priority is t product. I would lik productive equally ded ber 2017 w Shareholde weeks, Biotro and final pa
ti-HIV treat to impatien destined to maybe, just 9th clinical tones along ion to dem e of the Co shareholder been achiev head, we ha
f possibilitie y, BIT225 i
against addi ned and focu to retain fle ke to take th efforts dur dicated parti ers CH
atient in th ate the Com
ntly await fi
maybe, ther trial condu g the clinic monstrate so
rs is by patie ed during th ave every re n should no es capable o is only one ef that many itional viral used approa exibility in t his opportun ring the pas icipation an HAIRMAN’ n a giant ste he Company mpany's lea alysis of tria nal results. his disease, re is light at ucted by Bio cal developm
ently delive he past 12 m ason to be o
- t be viewe
- f delivering
- f hundreds
y opportuni targets. ach to capit the developm nity to than st12 months nd support. S ADDRES ep towards d y's Phase 2 ad compoun al data is, b Neverthele there is ho t the end of
ment pathw ce and prov he only wa ering quality months, as w
d as a singl g sustainabl s of Biotron ities reside i tal managem ment of gro nk our smal
SS TO THE demonstratin 2 HIV trial nd, BIT225, by necessity ess, we rem
a very long previous eig way for BIT ven results ay to achiev y data from c will be outlin Close focus le asset com e sharehold n compound in the Comp ment is emb
ll but dedica also like to
E W
E AGM ng that erad completed , benefits p y, frustrating main confiden the thousan tunnel. ght trials su
add crede ve the comm clinical trial ned in the C s on our cor
der value.
pany's comp bedded in o tunities align ated staff fo
Level 2, 6 Syd Tel: Fax: E-mail: info@ Website: www
dication of H treatment. atients abov gly slow so
nds of share uccessfully p e latest tria ence to our mercial out ls and suppo CEO’s presen re assets is p ur diversity tantial volum pound libra
ned, of cour
y fellow dire
66 Hunter Str dney NSW 2 (61-2) 9300 3 (61-2) 9221 6 @biotron.com w.biotron.com
HIV is possi The trial w ve and bey
many milli eholders of provided sou al caps off r belief in comes that
ntation. presenting n
me of evide ary, likely to ng model. O rse, to our l ermination ectors for th
reet 2000 344 6333 m.au m.au
ible. was
ittle ions this und
the are es. new rong ence
Our lead and heir
